Literature DB >> 18311751

The clinimetric properties of the World Health Organization Disability Assessment Schedule II in early inflammatory arthritis.

Murray Baron1, Orit Schieir, Marie Hudson, Russell Steele, Sousan Kolahi, Laeora Berkson, Francois Couture, M A Fitzcharles, Michel Gagné, Bruce Garfield, Andrzej Gutkowski, Harb Kang, Morton Kapusta, Sophie Ligier, Jean-Pierre Mathieu, Henri Ménard, Michael Starr, Michael Stein, Michel Zummer.   

Abstract

OBJECTIVE: To assess the clinimetric properties of a new health-related quality of life (HRQOL) instrument, the World Health Organization Disability Assessment Schedule II (WHODAS II), in patients with early inflammatory arthritis.
METHODS: Internal consistency as well as criterion, construct, and discriminative validity of the WHODAS II were assessed in 172 patients with early inflammatory arthritis who completed the WHODAS II, the Medical Outcomes Study Short Form 36 (SF-36), and other measures of disease severity, functioning, pain, depression, and resource use. Test-retest reliability of the WHODAS II was assessed by having a subset of 20 patients complete the WHODAS II a second time, 1 week after the first assessment.
RESULTS: The WHODAS II had high internal consistency (Cronbach's alpha = 0.96 for patients working or in school and 0.93 for patients not working or in school). Test-retest intraclass correlation coefficients of the WHODAS II total score and subscales ranged from 0.82-0.96. The WHODAS II total score was strongly correlated with the SF-36 physical component score (Kendall's tau-b 0.51, P < 0.001) and moderately correlated with the SF-36 mental component score (tau-b 0.43, P < 0.001). WHODAS II correlations with disease outcomes ranged from Kendall's tau-b 0.15-0.55. The WHODAS II significantly differentiated between every aspect of disease severity assessed with the exception of measures of health resource use.
CONCLUSION: The WHODAS II is a valid and reliable measure of HRQOL in cross-sectional studies of patients with early inflammatory arthritis. Research is still required to investigate potential item redundancy and determine its usefulness in longitudinal studies.

Entities:  

Mesh:

Year:  2008        PMID: 18311751     DOI: 10.1002/art.23314

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

1.  Developing the World Health Organization Disability Assessment Schedule 2.0.

Authors:  T Bedirhan Ustün; Somnath Chatterji; Nenad Kostanjsek; Jürgen Rehm; Cille Kennedy; Joanne Epping-Jordan; Shekhar Saxena; Michael von Korff; Charles Pull
Journal:  Bull World Health Organ       Date:  2010-05-20       Impact factor: 9.408

2.  Feasibility, reliability, and validity of the Japanese version of the 12-item World Health Organization Disability Assessment Schedule-2 in preoperative patients.

Authors:  Mitsuru Ida; Yusuke Naito; Yuu Tanaka; Yasunori Matsunari; Satoki Inoue; Masahiko Kawaguchi
Journal:  J Anesth       Date:  2017-04-04       Impact factor: 2.078

3.  Validity of the 12-item World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) in individuals with Huntington disease (HD).

Authors:  Noelle E Carlozzi; Anna L Kratz; Nancy R Downing; Siera Goodnight; Jennifer A Miner; Nicholas Migliore; Jane S Paulsen
Journal:  Qual Life Res       Date:  2015-01-31       Impact factor: 4.147

4.  Reliability and validity of the 12-item WHODAS 2.0 in patients with Kashin-Beck disease.

Authors:  Mohammad Imran Younus; Di-Miao Wang; Fang-Fang Yu; Hua Fang; Xiong Guo
Journal:  Rheumatol Int       Date:  2017-04-24       Impact factor: 2.631

5.  Utility of the twelve-item World Health Organization Disability Assessment Schedule II (WHO-DAS II) for discriminating depression "caseness" and severity in Spanish primary care patients.

Authors:  Juan V Luciano; José L Ayuso-Mateos; Ana Fernandez; Jaume Aguado; Antoni Serrano-Blanco; Miquel Roca; Josep M Haro
Journal:  Qual Life Res       Date:  2009-12-18       Impact factor: 4.147

6.  The 12-item World Health Organization Disability Assessment Schedule II (WHO-DAS II): a nonparametric item response analysis.

Authors:  Juan V Luciano; José L Ayuso-Mateos; Jaume Aguado; Ana Fernandez; Antoni Serrano-Blanco; Miquel Roca; Josep M Haro
Journal:  BMC Med Res Methodol       Date:  2010-05-20       Impact factor: 4.615

7.  Validation of the "World Health Organization Disability Assessment Schedule, WHODAS-2" in patients with chronic diseases.

Authors:  Olatz Garin; Jose Luis Ayuso-Mateos; Josué Almansa; Marta Nieto; Somnath Chatterji; Gemma Vilagut; Jordi Alonso; Alarcos Cieza; Olga Svetskova; Helena Burger; Vittorio Racca; Carlo Francescutti; Eduard Vieta; Nenad Kostanjsek; Alberto Raggi; Matilde Leonardi; Montse Ferrer
Journal:  Health Qual Life Outcomes       Date:  2010-05-19       Impact factor: 3.186

8.  Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey.

Authors:  Renata M Sousa; Cleusa P Ferri; Daisy Acosta; Emiliano Albanese; Mariella Guerra; Yueqin Huang; K S Jacob; A T Jotheeswaran; Juan J Llibre Rodriguez; Guillermina Rodriguez Pichardo; Marina Calvo Rodriguez; Aquiles Salas; Ana Luisa Sosa; Joseph Williams; Tirso Zuniga; Martin Prince
Journal:  Lancet       Date:  2009-11-28       Impact factor: 79.321

9.  Measuring disability across cultures--the psychometric properties of the WHODAS II in older people from seven low- and middle-income countries. The 10/66 Dementia Research Group population-based survey.

Authors:  Renata M Sousa; Michael E Dewey; Daisy Acosta; A T Jotheeswaran; Erico Castro-Costa; Cleusa P Ferri; Mariella Guerra; Yueqin Huang; K S Jacob; Juana Guillermina Rodriguez Pichardo; Nayeli Garcia Ramírez; Juan Llibre Rodriguez; Marina Calvo Rodriguez; Aquiles Salas; Ana Luisa Sosa; Joseph Williams; Martin J Prince
Journal:  Int J Methods Psychiatr Res       Date:  2010-03       Impact factor: 4.035

10.  Increased GABA+ in People With Migraine, Headache, and Pain Conditions- A Potential Marker of Pain.

Authors:  Aimie L Peek; Andrew M Leaver; Sheryl Foster; Georg Oeltzschner; Nicolaas A Puts; Graham Galloway; Michele Sterling; Karl Ng; Kathryn Refshauge; Maria-Eliza R Aguila; Trudy Rebbeck
Journal:  J Pain       Date:  2021-06-25       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.